SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Abstract

SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.

DNA Adducts in Cancer Chemotherapy

“…46 Although SarCNU showed better efficacy than carmustine against gliomas, 47,48 it caused severe pulmonary toxicity in phase II trials and is not approved by the U.S. FDA. 49,50 Other compounds, including ranimustine 23, nimustine 24, and fotemustine 25, are approved to be used in Japan, Japan/China, and Europe, respectively. However, they have not gained approval from the U.S. FDA.…”

“…For example, SarCNU 22 was designed by using N -methylglycinamide as a carrier and showed a good selectivity for cancer cells via the extraneuronal monoamine transporter (EMT) . Although SarCNU showed better efficacy than carmustine against gliomas, , it caused severe pulmonary toxicity in phase II trials and is not approved by the U.S. FDA. , Other compounds, including ranimustine 23 , nimustine 24 , and fotemustine 25 , are approved to be used in Japan, Japan/China, and Europe, respectively. However, they have not gained approval from the U.S. FDA …”

Alkylating Agents

“…The National Cancer Institute supported several clinical trials to assess response rate, survival and effects of treatment, in malignant gliomas and metastatic colorectal cancer (Wong et al, 2006).…”